Journal of Interventional Medicine最新文献

{"title":"Direct transmesenteric venous interventions in the acute post liver transplant setting","authors":"Keshav Anand MD,MPH,&nbsp;Luis Garza,&nbsp;Glenn Halff MD,&nbsp;Tarunjeet Klair MD,&nbsp;Francisco Cigarroa MD,&nbsp;Rajeev Suri MD,&nbsp;Jorge Lopera MD","doi":"10.1016/j.jimed.2020.09.001","DOIUrl":"10.1016/j.jimed.2020.09.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Portal venous thrombosis and stenosis are uncommon but serious causes of liver transplant graft failure. While surgical thrombectomy can be utilized for the treatment of portal steno-occlusive disease, venous interventions with IR have been performed with encouraging results.</p></div><div><h3>Case description</h3><p>69-year-old female with non-alcoholic steatohepatitis cirrhosis who received a liver transplant complicated by portal vein thrombus. Efforts between transplant surgery and IR allowed for successful thrombus removal via direct SMV access.</p></div><div><h3>Results</h3><p>The advantages of direct SMV access with the surgery team include direct approach to accessing thrombus, sparing of liver parenchyma, and significant hemostatic control.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the preoperative gap of precision hepatectomy: Superstable homogeneous iodinated formulation technology","authors":"Zhe Wang,&nbsp;Junqing Wang,&nbsp;Gang Liu","doi":"10.1016/j.jimed.2020.10.010","DOIUrl":"10.1016/j.jimed.2020.10.010","url":null,"abstract":"<div><p>The in-situ post-embolization fluorescence-guided hepatectomy for hepatocellular carcinoma (HCC) requires precise embolic formulation that meets both preoperative and intraoperative needs of hepatobiliary surgeons. In this Editorial, we highlight the development of <strong><u>S</u></strong>uperstable <strong><u>H</u></strong>omogeneous <strong><u>I</u></strong>odinated <strong><u>F</u></strong>ormulation <strong><u>T</u></strong>echnology (SHIFT) for locoregional HCC treatment. It is believed that such an intelligent solution could resolve unmet formulation needs and make a major stride to bridge the preoperative gap of precision hepatectomy.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.10.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39734404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma","authors":"Murtuza Razi,&nbsp;Gu Jianping,&nbsp;He Xu,&nbsp;Mohammed Jameeluddin Ahmed","doi":"10.1016/j.jimed.2020.10.006","DOIUrl":"10.1016/j.jimed.2020.10.006","url":null,"abstract":"<div><p>Transarterial chemoembolization (TACE) is a minimally invasive procedure involving intra-arterial catheter-based chemotherapy to selectively administer high doses of cytotoxic drugs to the tumor bed along with ischemic necrosis induced by arterial embolization. Chemoembolization forms the essential core of management in patients with hepatocellular carcinoma (HCC) who are not suitable for curative therapies such as transplantation, resection, or percutaneous ablation. TACE of hepatic cancer(s) has proven to be helpful in achieving local tumor control, and has supported the ability to prevent tumor progression, prolong patient life, and manage patient symptoms. Recent data have demonstrated that, in patients with single-nodule HCC ≤3 ​cm without vascular invasion, the 5-year overall survival with TACE was found to be comparable with hepatic resection and radiofrequency ablation. Used for several years, Lipiodol continues to play a vital role as a tumor-seeking and radiopaque drug delivery vector in interventional oncology. Efforts have been made to enhance the administration of chemotherapeutic agents to tumors. Compared with conventional TACE, drug-eluting bead TACE is a fairly new drug delivery embolization technique that permits fixed dosing and has the ability to provide sustained release of anticancer agents over a period of time. The present review discusses the basic procedure of TACE and its properties, and the effectiveness of conventional and drug-eluting bead chemoembolization systems currently available or presently undergoing clinical evaluation.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39734406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new choice of stent for transjugular intrahepatic portosystemic shunt creation: Viabahn ePTFE covered stent/bare metal stent combination","authors":"Jiacheng Liu ,&nbsp;Jie Meng ,&nbsp;Chen Zhou ,&nbsp;Qin Shi ,&nbsp;Chongtu Yang ,&nbsp;Jinqiang Ma ,&nbsp;Manman Chen ,&nbsp;Bin Xiong","doi":"10.1016/j.jimed.2020.10.003","DOIUrl":"10.1016/j.jimed.2020.10.003","url":null,"abstract":"<div><h3>Objectives</h3><p>To compare the clinical outcomes in terms of structure and function between the insertion of a transjugular intrahepatic portosystemic shunt (TIPS) created with the Viabahn ePTFE covered stent/bare metal stent (BMS) combination and the Fluency ePTFE covered stent/BMS combination.</p></div><div><h3>Methods</h3><p>A total of 101 consecutive patients who received a TIPS from February 2016 to August 2018 in our center were retrospectively analyzed. Sixty-four subjects were enrolled in the Viabahn group and 37 were enrolled in the Fluency group. The geometry characteristics of the TIPS were calculated, and the associated occurrence of shunt dysfunction, survival, overt hepatic encephalopathy, and variceal rebleeding were evaluated.</p></div><div><h3>Results</h3><p>The technical success rate was 100%. After the insertion of the TIPS, the rate of shunt dysfunction during the first 3 months was significantly different between the Viabahn and Fluency groups (1.6% and 13.5%, respectively; p ​= ​0.024). Multivariate analysis indicated that the angle of portal venous inflow (α) was the only independent risk factor for shunt dysfunction (hazard ratio ​= ​1.060, 95% confidence interval ​= ​1.009–1.112, p ​= ​0.020). In addition, 3 months after the TIPS insertion, the α angle distinctly increased from 20.9° ​± ​14.3°–26.9° ​± ​20.1° (p ​= ​0.005) in the Fluency group but did not change significantly in the Viabahn group (from 21.9° ​± ​15.1°–22.9° ​± ​17.6°, p ​= ​0.798).</p></div><div><h3>Conclusions</h3><p>Shunt dysfunction was related to the α angle owing to the slight effect on the α angle after the implantation of the TIPS. The Viabahn ePTFE covered stent/BMS combination was more stable in structure and promised higher short-term stent patency compared with the Fluency ePTFE covered stent/BMS combination.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39734410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma","authors":"Lin Zheng ,&nbsp;Hailiang Li ,&nbsp;Jinhua Huang ,&nbsp;Jihoon Shin ,&nbsp;Suxia Luo ,&nbsp;Chenyang Guo ,&nbsp;Yan Zhao ,&nbsp;Fangkun Li","doi":"10.1016/j.jimed.2020.10.009","DOIUrl":"10.1016/j.jimed.2020.10.009","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the clinical significance of serum midkine (MDK) levels for the diagnosis of hepatocellular carcinoma (HCC) and evaluate the efficacy of interventional therapy.</p></div><div><h3>Methods</h3><p>Eighty-four patients with HCC were enrolled in this retrospective study. They received an interventional treatment. A follow-up was performed every 2 months, using magnetic resonance imaging, to determine whether the treatment should be continued. Serum alpha-fetoprotein (AFP) and MDK levels were measured at the first diagnosis and during the follow-ups, and the HCC detection rates based on the cutoff values of these two measurements were compared. The relationships between AFP and MDK and the clinical tumor characteristics and changes in APK and MDK before and after treatment were also compared using a rank sum test and χ² test, respectively. The prognostic significance of MDK for HCC was determined through regression analysis. A two-sided <em>P</em> ​&lt; ​0.05 was considered statistically significant.</p></div><div><h3>Results</h3><p>MDK expression was detected in 95.24% of the cases. Subgroup analysis revealed MDK expression in 95.35%, 95.12%, 85.19%, 86.67%, and 83.33% of the AFP-positive, AFP-negative, stage A Barcelona clinic liver cancer (BCLC-A), BCLC-A/AFP-positive, and BCLC-A/AFP-negative cases, respectively. MDK expression after the interventional treatment (66.7%) was significantly lower than that before the treatment (95.2%). The mean post-treatment MDK level was 0.67 ​ng/mL in patients with a positive response to therapy as compared with 3.66 ​ng/mL in those with no positive response. All patients were followed up for 18 months, and those positive for MDK expression before the intervention were more likely to relapse than patients without MDK expression. Subgroup analysis revealed the highest recurrence rate for patients who were positive for MDK expression before and after treatment.</p></div><div><h3>Conclusions</h3><p>Serum MDK may serve as a powerful complement to AFP in the diagnosis of HCC. MDK measurement may improve the detection rate of BCLC-A and AFP-negative HCC. Serum MDK may help to determine the vascular invasion and poor clinical staging of HCC tumors. Patients with MDK-positive HCC before treatment may be more prone to postoperative tumor progression.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.10.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model","authors":"Ning Wei ,&nbsp;Ziqiang Wu ,&nbsp;Dong Lu ,&nbsp;Jingkun Xiao ,&nbsp;Chunze Zhou ,&nbsp;Senlin Chu ,&nbsp;Weifu Lv","doi":"10.1016/j.jimed.2020.08.006","DOIUrl":"10.1016/j.jimed.2020.08.006","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to analyze the effects of transcatheter arterial embolization (TAE) combined with portal venous embolization (PVE) on the expression of MMP-2 in residual VX2 liver tumor tissues, liver function and non-embolic lobe regeneration.</p></div><div><h3>Methods</h3><p>A total of 72 rabbits were randomly divided into Sham, TAE, PVE and TAE ​+ ​PVE groups (n ​= ​18/group). The tissue samples from each group were taken at 6 ​h, 3 days and 7 days after interventional operation, respectively. MMP-2 expression was detected by immunohistochemistry, Real-time PCR, and Western-blotting. The main indicators (such as AST, ATL, and TBIL) of liver function and the volume of non-embolized hepatic lobes were measured in each group after operation. One-way ANOVA and Kruskal-wallis method were used for statistical analysis.</p></div><div><h3>Results</h3><p>The expression of MMP-2 mRNA and protein remained the highest in the Sham group, and the expression of MMP-2 mRNA and protein in TAE, PVE and TAE ​+ ​PVE groups were successively increased, and the expression of MMP-2 in TAE ​+ ​PVE group was always significantly higher than TAE group. The AST and ALT levels in each group on day 7 after operation showed a significant declination, and all groups have recovered to the preoperative baseline level and TBIL has a slight fluctuation in each group after operation with no statistical difference. On day 7 after operation, the increasing volume of non-embolized liver lobes in TAE ​+ ​PVE group showed a more significant effect than those in PVE group, but there was no statistical significance (37.62 ​± ​1.54 ​ml VS 36.18 ​± ​1.15 ​ml, P ​= ​0.881), and its volume was significantly higher than those in the sham group (27.03 ​± ​1.11 ​ml).</p></div><div><h3>Conclusion</h3><p>TAE ​+ ​PVE is considered to be an efficient and safe approach for treating rabbit VX2 liver transplantation tumor, but the expression of MMP-2 increased fastest after TAE ​+ ​PVE, which might promote tumor cell invasion and metastasis.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.08.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant","authors":"Qiao Deng,&nbsp;Shichao Zhang,&nbsp;Mingzhou Li,&nbsp;Guozhong Zhang,&nbsp;Wenfeng Feng","doi":"10.1016/j.jimed.2020.08.005","DOIUrl":"10.1016/j.jimed.2020.08.005","url":null,"abstract":"<div><h3>Objective</h3><p>To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.</p></div><div><h3>Methods</h3><p>Retrospective analysis of relevant data of patients using GPIs combined with oral antiplatelet therapy in Nanfang Hospital of Southern Medical University from December 2017 to December 2019. The study was approved by the ethics Committee of Nanfang Hospital of Southern Medical University. According to the random use of GPIs drugs, they were assigned to the eptifibatide group and tirofiban group. Basic data, platelet inhibition rates at baseline, 24h and 72h after administration, short-term major adverse cerebrovascular events, and bleeding complications were compared between the two groups.</p></div><div><h3>Results</h3><p>A total of 47 patients were included in this study, including 24 patients in eptifibatide group and 23 patients in tirofiban group. There was no significant difference in average age (53.75 <em>vs</em>. 53.91 years) and body mass index (BMI) (24.39 <em>vs</em>. 22.73 ​kg/m2) between eptifibatide group and tirofiban group. There was no significant difference in coagulation factor function (R), fibrinogen function (K), fibrinolysis function (EPL), comprehensive coagulation index (Cl), arachidonic acid pathway inhibition rate (AA%) and adenosine diphosphate inhibition rate (ADP%). However, the baseline level of residual platelet function MA (ADP) in eptifibatide group was significantly higher than that in tirofiban group (50.79 <em>vs</em>. 35.29 ​mm, P ​= ​0.0026). There was a statistical difference in the platelet aggregation function MA (65.38 <em>vs</em>. 62.54 ​mm, p ​= ​0.0442), the rate of spontaneous hemorrhagic stroke (4.3% <em>vs</em>. 0%) and the rate of asymptomatic minor bleeding (26.08% <em>vs</em>. 4.1%) in the two groups (P ​&lt; ​0.05).</p></div><div><h3>Conclusion</h3><p>Both eptifibatide and tirofiban can effectively inhibit platelets, but the effect of etifeptide is better than that of tirofiban in preventing intracranial microhemorrhage and asymptomatic cerebral infarction.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment options for pulmonary multifocal ground glass opacity type adenocarcinoma: Surgery combine thermal ablation?","authors":"Baodong Liu,&nbsp;Yi Zhang,&nbsp;Lei Su,&nbsp;Ruotian Wang","doi":"10.1016/j.jimed.2020.08.009","DOIUrl":"10.1016/j.jimed.2020.08.009","url":null,"abstract":"<div><h3>Objectives</h3><p>To retrospectively analyze the clinical results of the treatment of pulmonary multifocal adenocarcinoma presenting as ground glass opacity (GGO) by surgery and thermal ablation.</p></div><div><h3>Methods</h3><p>87 GGO-type pulmonary adenocarcinomas of 48 patients (14 males and 34 females; mean age: 59.7 years old ±9.9, range: 33–79 years old) had been treated from March 2015 to March 2019. Treatment means included 43 wedge resections, 7 segmentectomy, 17 lobectomies, and 20 thermal ablations. The indication selected for treatment means, safety, and local tumor progression rate were evaluated.</p></div><div><h3>Results</h3><p>No operation-related death occurred in all patients. 42 times of surgery were performed and 67 carcinomas were resected in 42 patients. 23 times of single-port Video-assisted thoracoscopic surgery (VATS), 8 times of two-port VATS and 11 times of three-port VATS were performed in total. There were 2 cases of air leak (exceeding 1 week), 1 case of chylothorax and 1 case of massive pleural effusion. Time duration of surgery was between 60 and 300mins (mean: 167mins). Intra-operative blood loss was between 5 and 300 ​mL (mean: 44 ​mL). Time of chest drainage was between 2 and 23d (mean 4.9d). Chest drainage volume was between 14 and 4633 ​mL (mean: 872 ​mL). Post-operation LOS (length of stay) was between 3 and 25d (mean: 6.2d). 15 times of thermal ablation were performed (1 case of air leak) and 20 carcinomas were ablated in 14 patients. The ablation time was between 30 and 120min (mean: 43min); post-operation LOS was between 1 and 10d (mean: 3.5d). During the mean follow-up period (16 months ​± ​13) (range: 5–60 months), no local tumor progression occurred.</p></div><div><h3>Conclusions</h3><p>Surgery and thermal ablation are safe and effective options for the treatment of pulmonary multifocal GGO-type adenocarcinoma.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.08.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconstructive treatment of symptomatic vertebral artery dissecting aneurysms with Willis covered stent: Initial experience","authors":"Yi Gu ,&nbsp;Li Chen ,&nbsp;Yang Zhang ,&nbsp;Mo Chen ,&nbsp;YongDong Li ,&nbsp;YueQi Zhu ,&nbsp;HaiTao Lu ,&nbsp;LiMing Wei ,&nbsp;PeiLei Zhang ,&nbsp;MinHua Li ,&nbsp;BinXian Gu ,&nbsp;Jin You ,&nbsp;Wu Wang","doi":"10.1016/j.jimed.2020.08.003","DOIUrl":"10.1016/j.jimed.2020.08.003","url":null,"abstract":"<div><h3>Background</h3><p>Symptomatic vertebral artery dissecting aneurysm (VADA) is a challenging disease with controversy on treatment strategy due to anatomic configuration and their nature. Moreover, the outcomes of reconstructive treatment have not been well established.</p></div><div><h3>Objective</h3><p>To evaluate the safety and efficacy of reconstructive endovascular treatment (EVT) for symptomatic VADAs with Willis covered stent.</p></div><div><h3>Methods</h3><p>We evaluated retrospectively 13 patients with symptomatic VADAs who treated with Willis covered stent, compared with stent-assisted coiling (SAC) on the characteristics, posttreatment course, angiographic and clinical follow-up outcomes at an average of 14.4 months (range, 3–48 months).</p></div><div><h3>Results</h3><p>A total of 33 patients with symptomatic VADAs were reviewed, 23 of these patients with ruptured VADAs. The technical successful rate is 100% respectively in Willis covered stent (Group A) and SAC (Group B, n ​= ​20). The initial complete occlusion rate was significant higher in group A (100%) than group B (30%) (p ​&lt; ​0.01). Major procedure-related complications were not significant different in the two groups. Serial follow-up angiograms revealed 5 recurrent VADAs in group B and no recurrence in group A (p ​&gt; ​0.05). No obvious in-stent stenosis and no re-hemorrhage and delayed ischemic symptoms during the follow-up period. The final angiograms of all survived patients demonstrated the complete occlusion rate was higher in group A (100%) than group B (80%), but no significant statistical difference (p ​&gt; ​0.05). Clinical outcomes were favorable in 31 (93.9%), severe disability occurred in one in group B, and only one death in group A. The final clinical outcomes were also not significant difference in the two groups (p ​&gt; ​0.05).</p></div><div><h3>Conclusions</h3><p>Our initial result demonstrated reconstructive EVT with Willis covered stent provides a viable approach for selected symptomatic VADAs involving the intracranial and extracranial segments, which is similar to favorable results with SAC. However, an expanded clinical experiences and larger cohort studies are needed.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.08.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular stent treatment of the iliac vein stenosis caused by a pelvic lymphocele secondary to gynecologic malignancy","authors":"Li Zhang,&nbsp;Xiang Li,&nbsp;Huaping Wu,&nbsp;Kaiping Lv,&nbsp;Cunliang Zeng,&nbsp;Huanhuan Song","doi":"10.1016/j.jimed.2020.08.004","DOIUrl":"10.1016/j.jimed.2020.08.004","url":null,"abstract":"<div><p>Over the past two years, 6 patients had iliac vein stenosis caused by radiation and pelvic lymphocele secondary to gynecologic malignancy. Patients had symptomatic lymphoceles induced lower limb edema. Poor treatment of symptomatic lymphoceles, compression symptoms persist, all patients were performed endovascular stent therapy, clinical symptoms of lower limb were completely relieved. Iliac vein stenosis caused by radiation and pelvic lymphocele secondary to gynecologic malignancy, endovascular stent placement is a nonsurgical alternative for the reestablishment of venous flow and sustained relief of symptoms.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2020.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}